ValiRx plc (GB:VAL) has released an update.
ValiRx plc, a life sciences company specializing in cancer therapeutics and women’s health, has clarified its financial situation following the announcement of its 2023 year-end results. The company reported a cash balance of £174,684 as of December 31, 2023, and subsequently raised approximately £1.8 million through a new share issue in January 2024. As of May 15, 2024, ValiRx’s cash position stands at roughly £1.1 million, indicating a solid financial footing as it continues to develop its early-stage medical innovations.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
